

From: Paul Gil <Paul.gil@sparktx.com>
Sent: Wednesday, November 08, 2017 6:54 PM
To: Morris, Nevitt
Subject: Re: BLA 125610 Spark Therapeutics/Information Request CM 11.08.17

Hi Nevitt,
I acknowledge receipt.
Regards,
Paul

----- Original Message -----

From: "Morris, Nevitt" <Nevitt.Morris@fda.hhs.gov>
Date: Wed, November 08, 2017 4:19 PM -0500
To: Jim Wang <jim.wang@sparktx.com>, Paul Gil <Paul.gil@sparktx.com>
CC: "Morris, Nevitt" <Nevitt.Morris@fda.hhs.gov>
Subject: BLA 125610 Spark Therapeutics/Information Request CM 11.08.17
Hi Jim and Paul:
We are submitting a CMC Information Request with responses expected by November 13, 2017:
1. For the tests listed in the "Table 15 Comparability Results for Side-by-Side Testing" submitted in section 3.2.P.2.3.3.1 Evaluation of Comparability, please provide the dates that the tests were performed.
2. Please provide updated stability data for the Engineering lots (#3) (b) (4) (DP) and (b) (4) (DS) at (b) (4), listed as ongoing in Table 5 of section 3.2.P.8.1. Do you have any plans for remaining containers, if there are any?

Thanks and please acknowledge receipt of this Information Request.

Nevitt

Nevitt Morris

Nevitt Morris, RN, BSN, BS
Consumer Safety Officer
Office of Tissues and Advanced Therapies
Center for Biologics Evaluation and Research (CBER)
U.S. Food and Drug Administration
Building 71, Room 4207
10903 New Hampshire Avenue
Silver Spring, MD 20993
Phone: (240) 402-8269
Fax: (301) 595-1303
Nevitt.Morris@fda.hhs.gov

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual(s) or entity(ies) named in the e-mail address. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please notify the sender immediately, and then please delete the message from your system.